CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
685.72MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.3880xvs all stocks
52-Week Change
-13.45%vs all stocks
Market Capitalization
685.72MUSDvs all stocks (USD)
Enterprise Value
424.07MUSDvs all stocks (USD)
Forward P/E
-3.99xvs Biotechnology peers
Price to Book (MRQ)
1.81xvs Biotechnology peers
Enterprise to EBITDA
-2.52xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-37.20%vs Biotechnology peers
Return on Equity (TTM)
-62.21%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-168.56MUSDvs all stocks (USD)
Net Income (TTM)
-154.10MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-130.21MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-86.09MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-145.82MUSDvs all stocks (USD)
Pre-tax Income
-134.04MUSDFY2025 · Dec 31, 2025Net Income
-134.04MUSDFY2025 · Dec 31, 2025EBIT
-145.82MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-145.21MUSDFY2025 · Dec 31, 2025Research & Development
121.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
24.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.34MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-134.04MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-136.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
-137.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
373.82MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-134.04MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
610.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.87MUSDFY2025 · Dec 31, 2025Other Non-cash Items
725.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.84MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.88MUSDFY2025 · Dec 31, 2025Capital Expenditures
-606.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-83.92MUSDFY2025 · Dec 31, 2025Sale of Investments
157.86MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
73.33MUSDFY2025 · Dec 31, 2025Other Financing Charges
361.13MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
383.36MUSDFY2025 · Dec 31, 2025Shares Outstanding
80.09MSharesUpdated Jul 18, 2026Float Shares
35.67MSharesUpdated Jul 18, 2026Shares Short
5.21MSharesUpdated Jul 18, 2026Short Ratio
10.81daysvs all stocks
Short % of Shares Outstanding
18.30%vs all stocks
% Held by Insiders
27.11%vs all stocks
% Held by Institutions
68.90%vs all stocks
Total Cash (MRQ)
252.28MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.15USDUpdated Jul 18, 2026Total Debt (MRQ)
2.64MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0071xvs Biotechnology peers
Current Ratio (MRQ)
6.16xvs Biotechnology peers
Book Value per Share (MRQ)
4.65USDUpdated Jul 18, 2026Total Assets
448.38MUSDvs all stocks (USD)
Total Current Assets
432.40MUSDFY2025 · Dec 31, 2025Total Liabilities
37.28MUSDFY2025 · Dec 31, 2025Total Non-current Assets
15.98MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.24MUSDFY2025 · Dec 31, 2025Total Current Liabilities
35.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
373.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
51.77MUSDFY2025 · Dec 31, 2025Accounts Payable
1.37MUSDFY2025 · Dec 31, 2025Short-term Debt
522.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.24MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-356.57MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
411.10MUSDvs all stocks (USD)
52-Week Low
7.00USDUpdated Jul 18, 202652-Week High
14.87USDUpdated Jul 18, 202652-Week Change
-13.45%vs all stocks
Beta
0.3880xvs all stocks
50-Day MA
8.15USDUpdated Jul 18, 2026200-Day MA
10.34USDUpdated Jul 18, 2026Avg 10-Day Volume
456.29KSharesUpdated Jul 18, 2026Avg 30-Day Volume
483.37KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.92USDUpdated Jul 18, 2026Other Income / Expense
432.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Altman Z-Score 9.91: safe zoneNotable
Altman Z-Score: 9.91
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Qianjiang Yongan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Supriya Lifescience Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Casper Sleep Inc
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Dyne Therapeutics Inc.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets
Shanghai Opm Biosciences Co., Ltd.
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets